I like the name, and I like the progress that CVS is making. This stock can go higher.
Even before reporting better-than-expected third-quarter results, the pharmacy giant was seeing more aggressive buying of its shares.
Let's review the charts and indicators of NVCR.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
Charts and indicators agree with Jim Cramer's bullish year-end call.
BAX saw shares plunge 10% last week on news of accounting irregularities and the charts appear bearish.
Let's review the charts once again.
The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
TherapeuticsMD and Thor Industries are in wholly unrelated sectors, but both stocks look undervalued over the long term.